Drug Profile


Alternative Names: AF 3012; NAD-441A; NM441; OPT-99; PrulifloxacinA brs; Pruvel; Quisnon; Sword; Sword 100; Unidrox

Latest Information Update: 18 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nippon Shinyaku
  • Developer Angelini Group; Cubist Pharmaceuticals; Lees Pharmaceutical Holdings; Merck & Co; Nippon Shinyaku; Optimer Pharmaceuticals
  • Class Antibacterials; Dioxolanes; Fluoroquinolones; Piperazines; Quinolones; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Gram-negative infections; Gram-positive infections; Pneumonia; Respiratory tract infections; Urinary tract infections
  • Phase III Acute exacerbations of chronic bronchitis; Prostatitis; Traveller's diarrhoea

Most Recent Events

  • 01 Jul 2015 Lees Pharmaceutical completes a phase III trial in Urinary tract infections in China (NCT02439632)
  • 13 May 2015 Prulifloxacin is still in phase-III development for Prostatitis, Traveller's diarrhoea and Acute exacerbations of chronic bronchitis in Italy
  • 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top